Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Patricia Smith who wrote (758)	2/28/2000 5:13:00 PM
From: Ian@SI	Respond to of 1139

You folk just aren't watching the right TV programs. A WSJ reporter was interviewed on CNBC at the time the stock took off. He stated: 1. Next generation Viagra is in Phase III trials which could lead to NDA within a year. 2. Same drug is in Phase I Clinical trial for Female Arousal. No competitors here yet. And perhaps an even larger market than Viagra. Women live longer than men; perhaps this will give them an additional reason to do so. ;-) 3. Mentioned the other areas of research in passing. 4. Stated that for a small cap like ICOS, even a small piece of the Viagra market share would have a major impact on its earnings. Referred to their drug as a probable blockbuster for its first NDA. And finally, to accentuate my getting lucky with their "next generation Viagra", on Wednesday, I sold some Mar45 PUTs hoping to get assigned. Thursday, I changed my mind and just bought a full position outright. Today it looks like I keep the premium from the PUTs sold, and have close to a 50% gain prior to settlement. Thank you CNBC and WSJ. Ian.